Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cad Cold is an oral fixed-dose combination therapy developed by Boffin Biotech for the symptomatic relief of the common cold, influenza, and upper respiratory allergies. It is formulated as a tablet containing paracetamol (an analgesic and antipyretic), phenylephrine (a nasal decongestant), and cetirizine (a second-generation antihistamine). Paracetamol acts centrally to reduce fever and alleviate pain by inhibiting prostaglandin synthesis. Phenylephrine is a selective alpha-1 adrenergic receptor agonist that induces vasoconstriction in the nasal mucosa, thereby reducing nasal congestion and swelling. Cetirizine is a selective peripheral H1 histamine receptor antagonist that prevents allergic symptoms such as sneezing, runny nose, and watery eyes without causing significant sedation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cetirizine + paracetamol + phenylephrine.